AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $222.49, giving the company a market capitalization of 394.11B. It carries a P/E multiple of 168.27 and pays a dividend yield of 2.9%.
As of 2026-01-31, AbbVie(ABBV) stock has fluctuated between $219.56 and $224.02. The current price stands at $222.49, placing the stock +1.3% above today's low and -0.7% off the high.
The AbbVie(ABBV)'s current trading volume is 6.6M, compared to an average daily volume of 7.11M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
AbbVie entered a voluntary agreement with the Trump administration to invest $100 billion in U.S. research and manufacturing over the next decade and to expand...
Key Points AbbVie is a well-established drugmaker with fast-growing immunology products and a solid dividend program. Abivax could challenge pharmaceutical gi...
West Pharmaceutical Services recently announced a definitive agreement to sell all manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery Sys...
Analyst ratings
63%
of 32 ratingsMore ABBV News
On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE:ABBV) a...
The Trump administration has announced the names of 15 drugs targeted for Medicare price negotiations for 2028. The new list of branded medications announced by...
Citi lowered the firm’s price target on AbbVie (ABBV) to $230 from $235 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma gro...
It doesn't look like the company will end up in the arms of an acquirer soon, after all. Monday was generally a good day for the stock market; nevertheless, so...
These stocks offer highly attractive dividends and staying power. Country music singer Willie Nelson was a relatively young 48 when he released a song with the...
(RTTNews) - Merck & Co Inc. (MRK) is no longer in discussions to acquire biotech company Revolution Medicines, according to a report from the Wall Street Journa...
In mid-January 2026, AbbVie reported positive Phase 3 results for its bispecific antibody epcoritamab in relapsed/refractory diffuse large B-cell lymphoma, and...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.